GE Healthcare Introduces Peptide Separation System

GE Healthcare has announced the introduction of Ettan nanoLC, a bio-inert nanoscale peptide separation system that is designed to deliver reproducible performance and is ideal for 1D-liquid chromatography proteomics applications upstream from electrospray ionisation mass spectrometry or MALDI MS/MS applications.

The nanoLC extends the range of applications of GE Healthcare's family of Ettan chromatography systems, which includes Ettan LC system, Ettan microLC, and Ettan MDLC multidimensional liquid chromatography system.

GE Healthcare claims that, the nano LC is suited for those with limited funding requiring a dedicated 1DLC system who don't want to compromise on the high sensitivity enabled by our LC platform.

The instrument's low dead volumes ensure minimum peak broadening and consistent peak concentrations for maximum sensitivity and resolution.

"The Ettan nanoLC platform includes the high quality components GE Healthcare customers have come to value in our AKTA chromatography systems," says Jasmine Gruia-Gray, global marketing director, Protein Discovery at GE Healthcare.

"The bio-inert system offers unique advantages for peptide separation of labile phosphopeptides upstream from electrospray ionisation MS."

Integrated system components include a flow splitter that is designed to ensure gradient elution at flow rates as low as 200 nl/min, UV and conductivity monitors, the P-905 pump, a pressure sensor, and biocompatible flow path and pump heads.

The Peltier-cooled Autosampler A-905 allows injection of as little as 100 nl of sample from vials or microtiter plates.

Control and evaluation of the chromatographic process can be achieved using GE Healthcare's UNICORN software or via a virtual interface with the MS software module.